Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.39
- Piotroski Score 8.00
- Grade Overweight
- Symbol (IRWD)
- Company Ironwood Pharmaceuticals, Inc.
- Price $3.42
- Changes Percentage (2.4%)
- Change $0.08
- Day Low $3.26
- Day High $3.50
- Year High $15.70
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $18.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.78
- Trailing P/E Ratio -0.94
- Forward P/E Ratio -0.94
- P/E Growth -0.94
- Net Income $-1,002,239,000
Income Statement
Quarterly
Annual
Latest News of IRWD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ironwood Pharmaceuticals, Inc. (IRWD): The Best Multibagger Penny Stock of 2025?
A list of the top 10 Multibagger Penny Stocks of 2025 includes Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). IRWD focuses on gastrointestinal products, showing growth potential through acquisitions a...
By Yahoo! Finance | 2 months ago -
Ironwood Pharmaceuticals (NASDAQ:IRWD) shareholders have endured a 49% loss from investing in the stock three years ago
Long-term investors in Ironwood Pharmaceuticals have experienced significant losses, with the share price down 49% in three years, falling short of market returns. Fundamental analysis is crucial to u...
By Yahoo! Finance | 3 months ago -
Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD)
Julie Mchugh, Director at Ironwood Pharmaceuticals Inc, sold 22,766 shares at $6.29 each, now owning 139,528 shares. The company focuses on gastrointestinal medicines and has a market cap of $1.014 bi...
By Yahoo! Finance | 5 months ago
